Henley in Arden, 26 March 2013. Venture capital fund manager Mercia Fund Management has announced its first EIS Fund investments as part of its Mercia Growth Fund 1. Warwick Audio Technologies and nanoTherics will receive investment alongside syndicate investors. Warwick Audio Technologies develops a unique Flat Flexible Loudspeaker technology, which is fundamentally a flat and
What Mercia Fund Management says: “The budget was set in the context for every one job lost in the public sector, 6 are created in the private sector and that a majority of this job growth is within SMEs. The budget was set as a budget for the ‘Aspiration Nation’. We have campaigned hard for
Henley-in-Arden, 15 March 2013. Venture capital fund manager Mercia Fund Management (MFM) has announced that its first Open House event aimed at companies seeking Seed Enterprise Investment Scheme (SEIS) start-up investment or EIS (expansion capital for growing businesses) investment is taking place on 16 April 2013 at Forward House in Henley-in-Arden, Warwickshire. Collectively with Mercia
London, UK, 7 March 2013 – PolyTherics Limited (“PolyTherics”), a provider of solutions for the development of better biopharmaceuticals, announces that it has received an undisclosed milestone payment from Celtic Pharma Holdings (“Celtic”), the international healthcare group, triggered by further progress on their haematology alliance to produce longer-acting versions of blood factor proteins. In 2012
Henley-in-Arden, 6 March 2013. Venture capital fund manager Mercia Fund Management has launched Mercia Growth Fund 2, its second hybrid EIS/SEIS fund. Mercia Growth Fund 2 offers the flexibility to invest either in EIS or SEIS, while enabling investors to maximise tax efficiency. Dr. Mark Payton, Managing Director of Mercia Fund Management commented on the
First-in-Class Anabolic Catabolic Transforming Agent Holds Promise in Treating Cancer Cachexia, Age-Related Sarcopenia OXFORD, UK – March 4, 2013 – PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia. The agent’s unique
Henley in Arden, 18 February 2013. Venture capital fund manager Mercia Fund Management has today announced that Forward Group, an evergreen private equity fund, has become a shareholder. The move strengthens Mercia Fund Management’s position as a provider of venture capital and related services. Terms of the investment were not disclosed. Run by a team
OXFORD, UK – 16 January 2013 – PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, today announced the award of a US$3.3 million contract from the US Defense Threat Reduction Agency (DTRA) to develop biodefence vaccine adjuvants using the company’s proprietary PolyMAP technology to help improve the safety and efficacy of two vaccines candidates:
Mercia Growth Fund SEIS investment opportunity closed within three months Birmingham, 19 November 2012. Mercia Fund Management (MFM) today announced an over subscription to the SEIS portion of its Mercia Growth Fund, less than three months after the fund’s launch. The Mercia Growth Fund, a ‘hybrid’ fund offering both Seed EIS (SEIS) and later stage
SALT LAKE CITY, Utah, 2012-11-12 – Allinea Software shifted the performance landscape at SC12 today with the announcement of a new performance analysis tool, Allinea MAP. Better known for their high-performance, scalable parallel debugger, Allinea DDT, the company has taken an unusual tack in developing the new product. “We worked with a range of leading